Providing continuity of care across multiple care settings

Abstract

To provide a method of improving cares by transferring and treating information on a patient, specifically information related to risks of developing pressure ulcers when the patient is cared in a plurality of settings.SOLUTION: A method includes the steps of: deciding to transfer a patient from a first care setting to a second care setting; performing a first assessment of the patient in the first care setting; preparing a transfer record of the assessment; and transferring the transfer record with the patient to the second care setting.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] Cross-reference to related patent applications This application claims the benefit of U.S. Provisional Patent Application No. 62 / 587,337, filed November 16, 2017, and U.S. Provisional Patent Application No. 62 / 693,810, filed July 3, 2018. The entire contents of these applications are incorporated herein by reference.

[0002] The present disclosure provides a method for improving care by transferring and handling patient information, particularly information related to risk of developing pressure ulcers, when patients receive care in multiple settings. [Background technology]

[0003] Skin is the largest organ in the human body. It is easily exposed to various types of injury and trauma. Ulcers can form when the skin and surrounding tissues are unable to redistribute external pressure and mechanical forces. Prolonged and continuous exposure to even moderate pressure, such as the pressure on the skin surface on the back of a supine patient caused by the patient's weight, can lead to pressure ulcers. In the presence of other injuries, such as neuropathy and peripheral tissue weakness that can be induced by diabetes, even periodic exposure to moderate pressure and stress can lead to ulcers, such as foot ulcers.

[0004] Pressure ulcers affect approximately 2.5 million people annually in the United States and a similar number in the European Union. In long-term acute care settings, up to 25% of elderly, immobile patients develop pressure ulcers. Infections and other complications from pressure ulcers are responsible for the deaths of approximately 60,000 patients in the United States annually.

[0005] It is desirable not only for patients but also for society to detect tissue damage and intervene with appropriate treatment before the skin breaks down to prevent further deterioration of the underlying tissue. The average cost of treating pressure-induced damage is only $2,000 at the earliest visible signs (stage 1 ulcer), but rises to $129,000 when the ulcer becomes deep enough to expose muscle or bone (stage 4 ulcer). Currently, patients typically receive universal prophylaxis of pressure ulcers, which means that the prophylaxis is not targeted to any specific anatomical site. Patients receive targeted localized treatment of the ulcer only after the ulcer has reached a point where it can be identified by visual assessment. The current standard for detecting pressure ulcers is by visual inspection, which is subjective, unreliable, untimely, and has low specificity. Thus, even if a patient has signs of skin inflammation and the development of an ulcer, the patient will not receive targeted localized treatment for the developing ulcer. Instead, the inflammation continues and a full-blown ulcer develops.

[0006] In current practice, an independent assessment of a patient's risk of developing a pressure ulcer is performed upon arrival in a care setting. This lack of knowledge from the previous care setting can reduce the quality of care received in the new care setting. Summary of the Invention

[0007] In one aspect, the present disclosure provides and includes a method for identifying and providing an appropriate level of pressure ulcer care to a patient based on multiple subepidermal moisture (SEM) measurements. In some aspects, a patient is provided with increasingly more effective interventions for a pressure ulcer based on changes in SEM measurements. In some aspects, a patient is provided with less intensive interventions for a pressure ulcer based on changes in SEM measurements.

[0008] 1. A method of providing continuity of care to a patient during a transfer between care settings, the method comprising: determining to transfer the patient from a first care setting to a second care setting; performing a first assessment of the patient at the first care setting; creating a transfer record for the assessment; and transferring the transfer record with the patient to the second care setting.

[0009] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of treatment for a pressure ulcer, the method comprising the steps of: assessing a patient for their risk of a pressure ulcer upon admission to a nursing home, the assessing step including taking a first plurality of subepidermal moisture (SEM) measurements of the patient; calculating a first delta value from a portion of the first plurality of SEM measurements; determining whether the first delta value exceeds a first threshold; administering a level-0 first intervention if the first delta value does not exceed the first threshold; and administering a level-N first intervention if the first delta value exceeds the first threshold, wherein N is an integer and N has a value greater than or equal to 1. In a further aspect, the disclosure provides and includes: performing a second plurality of SEM measurements on the patient at a first predetermined frequency corresponding to a level of intervention to be administered; calculating a second delta value from a portion of the second plurality of SEM measurements; determining whether the second delta value exceeds a second threshold; continuing to administer the first intervention if the second delta value does not exceed the second threshold; continuing to perform the plurality of SEM measurements at the first predetermined frequency if the second delta value does not exceed the second threshold; administering a second intervention at level-M if the second delta value exceeds the second threshold, where M is an integer and M is greater than N; and performing the plurality of SEM measurements at the second predetermined frequency corresponding to level-M if the second delta value exceeds the second threshold. In yet a further aspect, the present disclosure provides and includes determining whether the second delta value is less than a third threshold, administering a level-(N-1) intervention if the second delta value is less than the third threshold and if the first intervention is not level-0, and taking a plurality of SEM measurements at a predetermined frequency corresponding to level-(N-1) if the second delta value is less than the third threshold.

[0010] In one aspect, the present disclosure provides and includes a method for slowing the progression of development of a pressure ulcer in a patient in need thereof, the method comprising the steps of identifying a current intervention at level-K received by the patient, taking a plurality of subepidermal moisture (SEM) measurements on the patient, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a first threshold, continuing to administer the current intervention if the delta value does not exceed the first threshold, continuing to take the plurality of SEM measurements at a predetermined frequency corresponding to level-K if the delta value does not exceed the first threshold, administering a new intervention at level-N if the delta value exceeds the first threshold, where N has a value greater than K, and administering the new intervention at level-N if the delta value exceeds the first threshold, where N has a value greater than K. In a further aspect, the present disclosure provides and includes determining whether the delta value is less than a second threshold, administering a level-L intervention if the delta value is less than the second threshold, where L has a non-negative value less than K, and taking a plurality of SEM measurements at a predetermined frequency corresponding to level-L if the delta value is less than the second threshold.

[0011] In one aspect, the present disclosure provides and includes a method for stratifying a group of patients in a nursing home based on pressure ulcer risk, the method including the steps of taking a plurality of subepidermal moisture (SEM) measurements for each patient, calculating a delta value from a portion of the plurality of SEM measurements for each patient, assigning a level of care to each patient based on whether each delta value exceeds any value in a set of thresholds corresponding to N levels of care, and reorganizing the group of patients based on each of the levels of care assigned to the patients.

[0012] In one aspect, the present disclosure provides and includes a method for reducing the incidence of pressure ulcers in patients admitted to a nursing home, the method comprising the steps of: assessing the patient for risk of pressure ulcers upon admission to the nursing home, the assessing step including taking a first plurality of subepidermal moisture (SEM) measurements of the patient; calculating a first delta value from a portion of the first plurality of SEM measurements; determining whether the first delta value exceeds a first threshold; administering a first intervention at level-0 if the first delta value does not exceed the first threshold; and administering a level-N intervention if the first delta value exceeds the first threshold, wherein N is an integer and N has a value greater than or equal to 1.

[0013] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a protective cream to the patient's heel, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements on the patient's heel; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the protective cream to the patient's heel if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every two hours if the delta value exceeds the threshold value.

[0014] In one aspect, the disclosure provides and includes a method for identifying and treating a patient in need of neuromuscular stimulation of the patient's heel, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's heel; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; administering neuromuscular stimulation to the patient's heel if the delta value exceeds the threshold value; and taking a plurality of SEM measurements hourly if the delta value exceeds the threshold value.

[0015] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a topical cream to the patient's heel, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements on the patient's heel; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the topical cream to the patient's heel if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every 30 minutes if the delta value exceeds the threshold value.

[0016] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a protective cream to the patient's sacrum, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the protective cream to the patient's sacrum if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every six hours if the delta value exceeds the threshold value.

[0017] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of neuromuscular stimulation to the patient's sacrum, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; administering neuromuscular stimulation to the patient's sacrum if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every four hours if the delta value exceeds the threshold value.

[0018] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a topical cream to the patient's sacrum, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the topical cream to the patient's sacrum if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every two hours if the delta value exceeds the threshold value. [Brief explanation of the drawings]

[0019] The patent or application file contains at least one drawing executed in color. Copies of this patent or application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0020] Aspects of the disclosure are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the detailed drawings, it is emphasized that the specific items shown are by way of example and for purposes of illustrative discussion of aspects of the disclosure. In this regard, the specification and drawings, considered singly or in combination, make apparent to those skilled in the art how aspects of the disclosure may be practiced.

[0021] [Figure 1] FIG. 1 illustrates an example of the entire selection process for pressure ulcer treatment based on SEM values ​​from nursing home admission to nursing home discharge in accordance with the present disclosure.

[0022] [Figure 2A] FIG. 2A is a sample visual assessment of healthy tissue in accordance with the present disclosure.

[0023] [Figure 2B] FIG. 2B is a plot of the average values ​​of SEM measurements taken at each location in and around a healthy sacrum in accordance with the present disclosure.

[0024] [Figure 3A] FIG. 3A is a sample of a visual assessment of damaged tissue in accordance with the present disclosure.

[0025] [Figure 3B] FIG. 3B is a plot of the average values ​​of SEM measurements taken at each location in and around the injured sacrum in accordance with the present disclosure.

[0026] [Figure 4] FIG. 4 is a diagram of a process for selecting and monitoring an intervention level based on the amount by which a delta value derived from an SEM measurement exceeds a threshold value in accordance with the present disclosure.

[0027] [Figure 5] FIG. 5 is an example of a workflow guidance matrix for selecting a new intervention level using a current intervention level and a new delta value in accordance with the present disclosure.

[0028] [Figure 6A] 6A, 6B and 6C show an example of the progression of delta values ​​over time for one patient at a single site of pressure ulcer development in accordance with the present disclosure. [Figure 6B] Same as above. [Figure 6C] Same as above.

[0029] [Figure 6D] FIG. 6D is an example plot of the change in delta values ​​over time for one patient at a single location with a decubitus ulcer in accordance with the present disclosure.

[0030] [Figure 7A] 7A and 7B are examples of methods for mapping areas of tissue damage according to the present disclosure. [Figure 7B] Same as above.

[0031] [Figure 8A]Figure 8A is an example of a currently recommended treatment decision pathway for preventing pressure ulcers in hospitalized patients that combines risk assessment and visual assessment.

[0032] [Figure 8B] FIG. 8B is an example of a current expanded treatment decision pathway for preventing pressure ulcers, as currently implemented in some healthcare facilities.

[0033] [Figure 9] FIG. 9 is an example flow chart of how an SEM scanner may be used in a stand-alone pressure ulcer prevention treatment in accordance with the present disclosure.

[0034] [Figure 10] FIG. 10 is an example flowchart of how an SEM scanner can be used to aid in further refining the expanded treatment decision pathway of FIG. 8B in accordance with the present disclosure.

[0035] [Figure 11] FIG. 11 illustrates the concept of providing continuity of care across multiple care settings in accordance with the present disclosure. DETAILED DESCRIPTION OF THE INVENTION

[0036] This specification is not intended to be a detailed catalog of all of the various ways in which this disclosure may be practiced or all of the features that may be added to the present disclosure. For example, features described in accordance with one embodiment may be incorporated in other embodiments, and features described in accordance with a particular embodiment may be deleted from that embodiment. That is, this disclosure contemplates that in some embodiments of this disclosure, any feature or combination of features specified herein may be excluded or omitted. Furthermore, multiple modifications and additions to the various embodiments suggested herein will become apparent to those skilled in the art in light of the present disclosure, but these do not depart from the present disclosure. In other instances, well-known structures, interfaces, and processes have not been shown in detail so as not to unnecessarily obscure the present invention. It is intended that no part of this specification be construed as resulting in a disclaimer of any portion of the full scope of the present invention. Accordingly, the following description is intended to describe some specific embodiments of the present disclosure, and not to fully specify all permutations, combinations, and variations thereof.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description of the present specification is for the purpose of describing particular aspects or embodiments only and is not intended to be limiting of the disclosure.

[0038] All publications, patent applications, patents, and other references cited herein are incorporated by reference in their entirety for the teachings relevant to the sentence and / or paragraph in which the reference occurs. References to technology used herein are intended to refer to technologies commonly understood in the art and include variations on those technologies or equivalent technical substitutions that would be apparent to one skilled in the art.

[0039] U.S. Patent Application Serial No. 14 / 827,375 ("the '375 Application") discloses an apparatus that uses radio frequency (RF) energy to measure subepidermal capacitance with bipolar sensors, which corresponds to the water content of a target area of ​​a patient's skin. The '375 Application also discloses an array of bipolar sensors of various sizes.

[0040] U.S. Patent Application No. 15 / 134,110 discloses a subepidermal moisture (SEM) measurement device similar to that shown in FIG. 3, which emits and receives RF signals at a frequency of 32 kHz via a single coaxial sensor to generate a bioimpedance signal, which is then converted into an SEM value.

[0041] Both U.S. Patent Application Nos. 14 / 827,375 and 15 / 134,110 are incorporated herein by reference in their entireties. However, the SEM values ​​herein may be measured by any similar or equivalent device or technique as would be apparent to one of ordinary skill in the art. For example, the device that measures the SEM values ​​herein may be a wired device, a wireless device, or a system comprising various components that communicate with each other.

[0042] Unless otherwise indicated in the context, it is specifically contemplated that the various features of the disclosure described herein can be used in any combination. Further, the present disclosure also contemplates that in some embodiments of the disclosure, it is possible to exclude or omit any feature or combination of features explicitly described herein.

[0043] The methods disclosed herein include and comprise one or more steps or actions for achieving the described method. Method steps and / or actions may be interchanged with one another without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of an embodiment, the order and / or use of specific steps and / or actions may be varied without departing from the scope of the present disclosure.

[0044] As used in the description of this disclosure and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly dictates otherwise.

[0045] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, but also does not include combinations when interpreted as alternatives ("or").

[0046] As used herein, the terms "about" and "approximately," when referring to measurements such as length, frequency, or SEM values, are meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or ±0.1% of the particular amount.

[0047] As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted as including X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y," and phrases such as "from about X to Y" mean "from about X to about Y."

[0048] As used herein, the term "sub-epidermal moisture" or "SEM" refers to an increase in tissue fluid and localized edema caused by vascular leakage and other changes that alter the underlying structure of injured tissue in the presence of continued pressure on the tissue, apoptosis, necrosis, and inflammatory processes.

[0049] As used herein, a "patient" can be a human or animal subject.

[0050] As used herein, "delta" refers to the calculated difference between two SEM values.

[0051] As used herein, the variables "K", "L", "M", and "N" are non-negative integers.

[0052] 1 illustrates an overall process 100 for selecting a pressure ulcer treatment based on SEM values ​​generated by SEM measurements taken using an SEM scanner according to the present disclosure, from nursing home admission to nursing home discharge. In some embodiments, the nursing home is selected from the group consisting of a hospital, assisted living facility, residential care facility, nursing home, long-term care facility, continuing care community, and independent living community. In some embodiments, the nursing home may be the patient's home or other residence, in which case the "entrance" step 102 is an initial assessment of the patient in their home by a nurse or other caregiver. In one embodiment, the schedule of interventions and assessment intervals used in the home environment may differ from the corresponding interventions and intervals used in the hospital.

[0053] In one aspect, in process 100, a newly admitted patient undergoes an intake assessment in step 104, which includes one or more of: visual inspection of a portion of the patient's skin; completion of at least a portion of a risk assessment protocol evaluating one or more of nutrition, mobility, physical activity, strength, and communication ability; and SEM measurements taken at one or more locations on the patient's skin. In one aspect, the SEM measurements may include taking multiple SEM measurements at a single "location" on the patient's skin. In one aspect, a "location" is considered an area rather than a single point, such that SEM measurements may be taken at spatially separated points within the location. For example, the location of the "heel" includes the medial, lateral, and posterior aspects of the heel area as well as the posterior portion of the sole of the foot.

[0054] In one aspect, once the assessment steps are complete, a determination is made in step 106 as to whether the patient is "out of alignment," i.e., whether the combined results of the various components of the assessment indicate that the patient has or is at risk for developing tissue damage that may lead to a pressure ulcer. Each component of the assessment may have individual criteria for the level of risk, e.g., a scoring system with thresholds that indicate unacceptable risk. In some aspects, there is a protocol for combining the criteria to generate a composite parameter that can be used to select a level of intervention.

[0055] In one embodiment, if the patient is determined to be at an acceptable risk level, the process proceeds to step 108, where the lowest level of intervention is implemented, referred to herein as "Level-Zero" or "Level-0." Proceeding from step 110 to 112, the patient is re-evaluated using at least the SEM measurement protocol in step 114 at a frequency, or conversely, time interval, associated with Level-0. Process 100 then loops back to step 106 to evaluate the results of the SEM measurements performed in step 114.

[0056] In one embodiment, if the patient is determined to be deviant in step 106, then processing proceeds to step 122, where a higher level of intervention is implemented. In some embodiments, there is a defined hierarchy of intervention levels, with each level implementing a more effective intervention than the next lower level. In some embodiments, each level also has a defined monitoring interval or frequency that indicates how often a set of SEM measurements should be taken, with higher levels generally having shorter intervals. In this example, the process was defined by the hospital or other governing body to move up one level to Level-1 intervention at this point. In other embodiments, step 122 may implement Level-2 or higher level intervention. Processing now enters a new loop beginning in step 130, where the patient is now monitored at Level-N frequency, where N ranges from 1 to n, and n is the highest level of intervention and monitoring defined.

[0057] In one embodiment, the patient's history is evaluated in step 134 to determine whether their condition is improving. If the patient's condition is improving, for example, as evidenced by a decrease in the delta value, then processing proceeds to step 142. In this example, step 142 continues to deliver the current level of intervention, and processing loops from step 140 through steps 130-132-134-142-140 until the delta value falls below the threshold. In one embodiment, the level of intervention can be reduced in step 142 based on the magnitude of the delta value as it decreases.

[0058] In one aspect, if the patient does not improve in step 134, the process proceeds to increase the level of intervention in step 138, provided that the skin has not broken down, i.e., not developed into an open ulcer, in step 136. If an open ulcer has developed, an SEM scan is now performed around the perimeter of the open wound to map inflammation or other signs of ulcer spread, in step 144. The ulcer itself is treated in step 148, and this secondary loop 144-146-148-150 continues until the wound is closed, at which point the process returns to step 130.

[0059] In some embodiments, at any point in process 100, patient discharge leads to step 118, where the patient's condition at the time of discharge or transfer is documented. In some embodiments, step 118 includes a final set of SEM measurements at one of multiple locations on the patient's body. In some embodiments, these locations include areas that did not receive intervention and areas not previously identified as at risk. In some embodiments, this information is provided to the receiving caregiver. The patient is then discharged or transferred in step 120.

[0060] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of treatment for a pressure ulcer, the method comprising the steps of: assessing a patient for their risk of a pressure ulcer upon admission to a nursing home, the assessing step comprising taking a first plurality of subepidermal moisture (SEM) measurements of the patient; calculating a first delta value from a portion of the first plurality of SEM measurements; determining whether the first delta value exceeds a first threshold; administering a level-0 first intervention if the first delta value does not exceed the first threshold; and administering a level-N first intervention if the first delta value exceeds the first threshold, wherein N is an integer and N has a value greater than or equal to 1.

[0061] In one aspect, the first plurality of SEM measurements are taken at and around one or more anatomical locations selected from the group consisting of the sternum, sacrum, heels, scapulae, elbows, ears, and other fleshy tissues of the patient. In certain aspects, the first plurality of SEM measurements are divided into subgroups for analysis based on the general locations at which the measurements are taken. In one aspect, the first plurality of SEM measurements are taken at locations located in one or more concentric circles around the anatomical location. In certain aspects, the first plurality of SEM measurements are taken at locations located on a line approximately equidistant from the anatomical location.

[0062] In one embodiment, the first delta value is determined by the difference between the largest SEM value and the smallest SEM value from a first plurality of SEM measurements collected. In some embodiments, the first delta value is determined by the difference between the largest SEM average of measurements taken at a first location and the smallest SEM average of measurements taken at a second location. In one embodiment, the first delta value is determined for a portion of the first plurality of SEM measurements comprising a subgroup defined by the locations taken. In some embodiments, the average SEM value at a location is obtained from 2, 3, 4, 5, 6, 7, 8, 9, 10, or more SEM values ​​measured at that location. In one embodiment, the first delta value is determined by the difference between SEM values ​​from measurements taken at two locations symmetrical to a centerline.

[0063] In some embodiments, the delta value can be calculated in multiple ways from multiple SEM measurements taken at a specific location or in the immediate vicinity of a specific location. In some embodiments, the multiple SEM measurements are taken within a predetermined pattern on the skin, and the delta value is calculated by subtracting the SEM value associated with the predetermined location within the pattern from the largest SEM value taken at other locations within the pattern. In some embodiments, the multiple SEM measurements are taken within a predetermined pattern on the skin, and the delta value is calculated by identifying the SEM value associated with the predetermined location within the pattern and subtracting the largest SEM value occurring at other locations within the pattern. In some embodiments, the average SEM value can be calculated from a portion of a set of SEM values ​​generated by multiple SEM measurements at a single location, and a delta value calculated as the largest difference between the average value of the same set and the single SEM value. In some embodiments, the delta value can be calculated as the ratio of the largest SEM value to the smallest SEM value within the set of SEM values.

[0064] In some embodiments, the first threshold is about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3 , 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, the first threshold value can range from 0.1 to 8.0, e.g., 0.1 to 1.0, 1.1 to 2.0, 2.1 to 3.0, 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0, 0.1 to 7.5, 0.5 to 8.0, 1.0 to 7.0, 1.5 to 6.5, 2.0 to 6.0, 3.0 to 5.5, 3.5 to 5.0, or 4.0 to 4.5, etc. In certain aspects, the first threshold value can be increased or decreased by a factor or multiple based on the values ​​provided herein. It will be understood that the threshold value is not limited by design, but rather, one of skill in the art will be able to select a predetermined value based on a given unit of SEM. In one aspect, the threshold values ​​of the present disclosure vary depending on the particular part of the patient's body where the measurement is taken or one or more characteristics of the patient, such as age, height, weight, family history, ethnicity, and other physical characteristics or medical conditions.

[0065] In some embodiments, N can range from 1 to 50, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 15, 1 to 20, 1 to 25, 1 to 30, 1 to 35, 1 to 40, or 1 to 45.

[0066] In one embodiment, N is determined by the amount by which the first delta value exceeds the first threshold. In some embodiments, the amount by which the delta value exceeds the threshold set at (N+1) is greater than the amount by which the delta value exceeds the threshold set at N. In one embodiment, the amount by which the delta value exceeds the threshold set at (N-1) is less than the amount by which the delta value exceeds the threshold set at N.

[0067] In some embodiments, Level-1 (N=1) intervention is applied to patients with delta values ​​that exceed the threshold by 100% or less of the threshold, e.g., delta values ​​that exceed the threshold by 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the threshold.

[0068] In some embodiments, Level-2 (N=2) intervention is applied to patients with delta values ​​exceeding the threshold by 150% or less of the threshold, e.g., delta values ​​exceeding the threshold by 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the threshold.

[0069] In one embodiment, Level-3 (N=3) interventions include delta values ​​exceeding the threshold by 200% or less of the threshold, e.g., 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less of the threshold. The term applies to patients with a delta value above the threshold by less than, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.

[0070] In one aspect, Level-4 (N=4) interventions include delta values ​​exceeding the threshold by 250% or less of the threshold, e.g., 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less of the threshold. The term "delta" applies to patients with a delta value above the threshold by less than, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.

[0071] In one aspect, a Level-5 (N=5) intervention is a delta value exceeding the threshold by 300% or less of the threshold, e.g., 295% or less, 290% or less, 285% or less, 280% or less, 275% or less, 270% or less, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less of the threshold. The term "delta" applies to patients with a delta value above the threshold by less than, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.

[0072] In one aspect, a Level-6 (N=6) intervention is a delta value exceeding the threshold by 350% or less of the threshold, e.g., 345% or less, 340% or less, 335% or less, 330% or less, 325% or less, 320% or less, 315% or less, 310% or less, 305% or less, 300% or less, 295% or less, 290% or less, 285% or less, 280% or less, 275% or less, 270% or less, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less of the threshold. or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less above the threshold.

[0073] In one aspect, a Level-7 (N=7) intervention is a delta value exceeding the threshold by 400% or less of the threshold, e.g., 395% or less, 390% or less, 385% or less, 380% or less, 375% or less, 370% or less, 365% or less, 360% or less, 355% or less, 350% or less, 345% or less, 340% or less, 335% or less, 330% or less, 35 ...0% or less 25% or less, 320% or less, 315% or less, 310% or less, 305% or less, 300% or less, 295% or less, 290% or less, 285% or less, 280% or less, 275% or less , 270% or less, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less above the threshold.

[0074] In one aspect, a Level-8 (N=8) intervention is a delta value exceeding the threshold by 450% or less of the threshold, e.g., 445% or less, 440% or less, 435% or less, 430% or less, 425% or less, 420% or less, 415% or less, 410% or less, 405% or less, 400% or less, 395% or less, 390% or less, 385% or less, 380% or less, 375% or less, 370% or less, 365% or less of the threshold. Below, 360% or less, 355% or less, 350% or less, 345% or less, 340% or less, 335% or less, 330% or less, 325% or less, 320% or less, 315% or less, 310% or less, 305% Below, 300% or less, 295% or less, 290% or less, 285% or less, 280% or less, 275% or less, 270% or less, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less Lower, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less Lower, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less , 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less above the threshold.

[0075] In one aspect, a Level-9 (N=9) intervention is a delta value exceeding the threshold by 500% or less of the threshold, e.g., 495% or less, 490% or less, 485% or less, 480% or less, 475% or less, 470% or less, 465% or less, 460% or less, 455% or less, 450% or less, 445% or less, 440% or less, 435% or less, 430% or less, 425% or less, 420% or less, 415% or less, 410% or less, 405% or less, 410% or less, 420% or less, 425% or less, 430% or less, 440% or less, 440% or less, 450% or less, 455% or less, 450% or less, 460% or less, 465% or less, 460% or less, 455% or less, 450% or less, 445% or less, 440% or less, 435% or less, 430% or less, 425% or less, 420% or less, 415% or less, 410% or less, 405% or less, 450% or less, 450% or less, 460% or less, 460% or less, 465% or less, 470% or less, 475% or less, 470% or less, 475% or less, 470% or less, 480% or less, 485% or less, 480% or less, 490% or less, 495% or less, 490% or less, 495% or less 00% or less, 395% or less, 390% or less, 385% or less, 380% or less, 375% or less, 370% or less, 365% or less, 360% or less, 355% or less, 350% or less, 345% or less, 340% or less, 335 % or less, 330% or less, 325% or less, 320% or less, 315% or less, 310% or less, 305% or less, 300% or less, 295% or less, 290% or less, 285% or less, 280% or less, 275% or less, 270% or less Lower, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 220% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 13 Applies to patients with delta values ​​exceeding the threshold by 5% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.

[0076] In one aspect, a Level -10 (N=10) intervention is a delta value exceeding the threshold by 550% or less of the threshold, e.g., 545% or less, 540% or less, 535% or less, 530% or less, 525% or less, 520% ​​or less, 515% or less, 510% or less, 505% or less, 500% or less, 495% or less, 490% or less, 485% or less, 480% or less, 475% or less, 470% or less, 465% or less, 460% or less, 455% or less, 450% or less, 445% or less, 440% or less of the threshold. % or less, 435% or less, 430% or less, 425% or less, 420% or less, 415% or less, 410% or less, 405% or less, 400% or less, 395% or less, 390% or less, 385% or less, 380% or less, 375% or less, 370% or less, 365% or less, 360% or less, 355% or less, 350% or less, 345% or less, 340% or less, 335% or less, 330% or less, 325% or less, 320% or less, 315% or less, 310% or less, 305% or less, 300% or less, 295% Below, 290% or less, 285% or less, 280% or less, 275% or less, 270% or less, 265% or less, 260% or less, 255% or less, 250% or less, 245% or less, 240% or less, 235% or less, 230% or less, 225% or less, 2 20% or less, 215% or less, 210% or less, 205% or less, 200% or less, 195% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less The term "delta" applies to patients with a delta value above the threshold by less than, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, 110% or less, 100% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.

[0077] In one embodiment, Level-N intervention is more effective than Level-0 intervention. In some embodiments, Level-(N+1) intervention is more effective than Level-N intervention. In one aspect, Level-(N-1) interventions are less effective than Level-N interventions.

[0078] In certain aspects, the assessing step of the present disclosure further comprises performing a visual assessment, hi one aspect, the visual assessment is performed according to NPUAP (National Pressure Ulcer Advisory Panel) guidelines.

[0079] In one aspect, the assessing step of the present disclosure further comprises performing a risk assessment, hi some aspects, the risk assessment is performed according to a test selected from the group consisting of the Braden scale, the Gosnell scale, the Norton scale, and the Waterlow scale.

[0080] In certain aspects, the disclosure further provides and includes: performing a second plurality of SEM measurements on the patient at a first predetermined frequency corresponding to the level of intervention to be administered; calculating a second delta value from a portion of the second plurality of SEM measurements; determining whether the second delta value exceeds a second threshold; continuing to administer the first intervention if the second delta value does not exceed the second threshold; continuing to perform the plurality of SEM measurements at the first predetermined frequency if the second delta value does not exceed the second threshold; administering a second intervention at level-M if the second delta value exceeds the second threshold, where M is an integer and M is greater than N; and performing the plurality of SEM measurements at the second predetermined frequency corresponding to level-M if the second delta value exceeds the second threshold.

[0081] In one embodiment, the predetermined frequency is selected from the group consisting of at least once every 72 hours, at least once every 48 hours, at least once every 24 hours, at least once every 12 hours, at least once every 8 hours, at least once every 6 hours, at least once every 4 hours, at least once every 3 hours, at least once every 2 hours, at least once every hour, and at least once every 30 minutes.

[0082] In one embodiment, the second plurality of SEM measurements is performed in accordance with paragraph 0061. In some embodiments, the second plurality of SEM measurements is performed at the same location as the first plurality of SEM measurements. In some embodiments, the second plurality of SEM measurements is performed at a portion of the same location as the first plurality of SEM measurements. In some embodiments, the second plurality of SEM measurements is performed near the location where the first plurality of SEM measurements was performed. In some embodiments, the second plurality of SEM measurements is performed at a different location than the location where the first plurality of SEM measurements was performed.

[0083] In some embodiments, the second delta value is determined by the difference between the maximum SEM value and the minimum SEM value from the collected second plurality of SEM measurements. In one embodiment, the second delta value is determined by the difference between the maximum SEM average of the measurements taken at the first location and the minimum SEM average of the measurements taken at the second location. In one embodiment, the second delta value is determined for a portion of the second plurality of SEM measurements comprised of subgroups defined by the locations taken.

[0084] In some embodiments, the second threshold is about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3 , 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, the second threshold can range from 0.1 to 8.0, such as 0.1 to 1.0, 1.1 to 2.0, 2.1 to 3.0, 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0, 0.1 to 7.5, 0.5 to 8.0, 1.0 to 7.0, 1.5 to 6.5, 2.0 to 6.0, 3.0 to 5.5, 3.5 to 5.0, or 4.0 to 4.5. In some aspects, the second threshold can be increased or decreased by a factor or multiple based on the values ​​provided herein. In one aspect, the second threshold can be the same as the first threshold. In some aspects, the second threshold can be greater than the first threshold. In one aspect, the second threshold can be less than the first threshold.

[0085] In some embodiments, M ranges from 2 to 50, such as 2 to 3, 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 15, 2 to 20, 2 to 25, 2 to 30, 2 to 35, 2 to 40, or 2 to 45.

[0086] In one embodiment, M is determined by the amount by which the second delta value exceeds a second threshold. In one aspect, the amount by which the delta value exceeds the threshold set at (M+1) is greater than the amount by which the delta value exceeds the threshold set at M. In one aspect, the amount by which the delta value exceeds the threshold set at (M-1) is less than the amount by which the delta value exceeds the threshold set at M.

[0087] In some embodiments, the level M intervention is selected according to paragraphs 0067 to 0076, with M replacing N.

[0088] In one aspect, the present disclosure further provides and includes determining whether the second delta value is less than a third threshold, administering a level-(N-1) intervention if the second delta value is less than the third threshold and if the first intervention is not level-0, and taking a plurality of SEM measurements at a predetermined frequency corresponding to level-(N-1) if the second delta value is less than the third threshold.

[0089] In some embodiments, the third threshold is about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3 , 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, the third threshold may range from 0.1 to 8.0, e.g., 0.1 to 1.0, 1.1 to 2.0, 2.1 to 3.0, 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0, 0.1 to 7.5, 0.5 to 8.0, 1.0 to 7.0, 1.5 to 6.5, 2.0 to 6.0, 3.0 to 5.5, 3.5 to 5.0, or 4.0 to 4.5. In some aspects, the third threshold may be increased or decreased by a factor or multiple based on the values ​​provided herein. In one aspect, the third threshold may be the same as the second threshold. In some aspects, the third threshold may be greater than the second threshold. In one aspect, the third threshold may be less than the second threshold. In one aspect, the third threshold may be the same as the first threshold. In one aspect, the third threshold may be greater than the first threshold, hi one aspect, the third threshold may be less than the first threshold.

[0090] In some embodiments, the second delta value can be 0.1 to 99.5% of the third threshold, e.g., 0.1 to 1%, 0.1 to 5%, 1 to 5%, 5 to 15%, 10 to 20%, 15 to 25%, 20 to 30%, 25 to 35%, 30 to 40%, 35 to 45%, 40 to 50%, 0.1 to 25%, 15 to 50%, 15 to 15%, 20 to 30%, 25 to 35%, 30 to 40%, 35 to 45%, 40 to 50%, 0.1 to 25 ... to 35%, 25 to 50%, 25 to 75%, 45 to 55%, 50 to 60%, 55 to 65%, 60 to 70%, 65 to 75%, 40 to 55%, 50 to 75%, 50 to 99.5%, 70 to 80%, 75% to 85%, 80 to 90%, 85 to 95%, 90 to 99.5%, 65 to 85%, or 75 to 99.5%, etc.

[0091] In one aspect, the present disclosure provides and includes a method of slowing the progression of development of a pressure ulcer in a patient in need thereof, comprising: identifying a current intervention at Level-K received by the patient; taking a plurality of subepidermal moisture (SEM) measurements on the patient; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a first threshold; continuing to administer the current intervention if the delta value does not exceed the first threshold; continuing to administer the plurality of SEM measurements at a predetermined frequency corresponding to Level-K if the delta value does not exceed the first threshold; administering a new intervention at Level-N if the delta value exceeds the first threshold, where N has a value greater than K; and administering the new intervention at Level-N if the delta value exceeds the first threshold; and administering the plurality of SEM measurements at a predetermined frequency corresponding to Level-N if the delta value exceeds the first threshold. In some aspects, the patient in need thereof is a patient experiencing a change in care, a change in mobility, a change in nutrition, a change in sensory perception, or a combination thereof. In one aspect, the patient in need thereof is a patient developing an open ulcer. In some embodiments, the patient in need thereof is a patient with an open ulcer healing. In one embodiment, the patient in need thereof is a patient undergoing a surgical procedure. In some embodiments, the patient in need thereof is a patient receiving spinal or sacral anesthesia during a surgical procedure. In one embodiment, the patient in need thereof is a patient undergoing a surgical procedure lasting 4 hours or more, e.g., 5 hours or more, 6 hours or more, 7 hours or more, 8 hours or more, 9 hours or more, 10 hours or more, 11 hours or more, or 12 hours or more. In some embodiments, the surgical procedure lasts for 1 hour or more, such as 2 hours or more, or 3 hours or more.

[0092] In one embodiment, the plurality of SEM measurements are performed in accordance with paragraph 0061. In an embodiment, the delta value is determined in accordance with paragraph 0062. In one embodiment, the first threshold is determined in accordance with paragraph 0064.

[0093] In some embodiments, K ranges from 2 to 50, such as 2 to 3, 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 15, 2 to 20, 2 to 25, 2 to 30, 2 to 35, 2 to 40, or 2 to 45.

[0094] In one embodiment, K is determined by the amount by which the delta value exceeds a threshold value. In one embodiment, the amount by which the delta value exceeds a threshold value set at (K+1) is greater than the amount by which the delta value exceeds a threshold value set at K. In one embodiment, the amount by which the delta value exceeds a threshold value set at (K-1) is less than the amount by which the delta value exceeds a threshold value set at K.

[0095] In some embodiments, the level K intervention is selected according to paragraphs 0067 to 0076, with K replacing N.

[0096] In certain aspects, the present disclosure further provides and includes determining whether the delta value is less than a second threshold, administering a level-L intervention if the delta value is less than the second threshold, where L has a non-negative value less than K, and taking a plurality of SEM measurements at a predetermined frequency corresponding to level-L if the delta value is less than the second threshold.

[0097] In some embodiments, the second threshold is determined in accordance with paragraph 0084.

[0098] In an embodiment, L can be K-1, K-2, K-3, K-4, K-5, K-6, K-7, K-8, K-9, or K-10. In one embodiment, L is K-1 if the delta value is 90 to 99.5% of the second threshold, e.g., 90 to 95%, 91 to 96%, 92 to 97%, 93 to 98%, 94 to 99%, or 95 to 99.5% of the second threshold, unless K-1 is less than 0, at which point L will be 0. In an embodiment, L is K-2 if the delta value is 80 to 89.9% of the second threshold, e.g., 80 to 85%, 81 to 86%, 82 to 87%, 83 to 88%, 84 to 89%, or 85 to 89.9% of the second threshold, unless K-2 is less than 0, at which point L will be 0. In one aspect, L is K-3 when the delta value is between 70 and 79.9% of the second threshold, e.g., between 70 and 75%, 71 and 76%, 72 and 77%, 73 and 78%, 74 and 79%, or 75 and 79.9% of the second threshold, etc., unless K-3 is less than 0, at which point L will be 0. In an aspect, L is K-4 when the delta value is between 60 and 69.9% of the second threshold, e.g., between 60 and 65%, 61 and 66%, 62 and 67%, 63 and 68%, 64 and 69%, or 65 and 69.9% of the second threshold, etc., unless K-4 is less than 0, at which point L will be 0. In one aspect, L is K-5 if the delta value is between 50 and 59.9% of the second threshold, e.g., between 50 and 55%, 51 and 56%, 52 and 57%, 53 and 58%, 54 and 59%, or 55 and 59.9% of the second threshold, unless K-5 is less than 0, at which point L will be 0. In an aspect, L is K-6 if the delta value is between 40 and 49.9% of the second threshold, e.g., between 40 and 45%, 41 and 46%, 42 and 47%, 43 and 48%, 44 and 49%, or 45 and 49.9%, at which point L will be 0, unless K-6 is less than 0.In one aspect, L is K-7 if the delta value is between 30 and 39.9% of the second threshold, e.g., between 30 and 35%, 31 and 36%, 32 and 37%, 33 and 38%, 34 and 39%, or 35 and 39.9% of the second threshold, etc., unless K-7 is less than 0, at which point L will be 0. In an aspect, L is K-8 if the delta value is between 20 and 29.9% of the second threshold, e.g., between 20 and 25%, 21 and 26%, 22 and 27%, 23 and 28%, 24 and 29%, or 25 and 29.9%, etc., at which point L will be 0, unless K-8 is less than 0. In one aspect, L is K-9 if the delta value is between 10 and 19.9% ​​of the second threshold, e.g., between 10 and 15%, 11 and 16%, 12 and 17%, 13 and 18%, 14 and 19%, or 15 and 19.9% ​​of the second threshold, etc., unless K-9 is less than 0, at which point L will be 0. In certain aspects, L is K-10 if the delta value is between 0.1 and 9.9% of the second threshold, e.g., between 0.1 and 5%, 1 and 6%, 2 and 7%, 3 and 8%, 4 and 9%, or 5 and 9.9%, etc., at which point L will be 0, unless K-10 is less than 0.

[0099] In one aspect, the present disclosure provides and includes a method for stratifying a group of patients in a nursing home based on pressure ulcer risk, the method including the steps of taking a plurality of subepidermal moisture (SEM) measurements for each patient, calculating a delta value from a portion of the plurality of SEM measurements for each patient, assigning a level of care to each patient based on whether each delta value exceeds any value in a set of thresholds corresponding to N levels of care, and reorganizing the group of patients based on each of the levels of care assigned to the patients.

[0100] In one aspect, the present disclosure provides and includes a method for reducing the incidence of pressure ulcers in patients admitted to a nursing home, the method comprising the steps of: assessing the patient for risk of pressure ulcers upon admission to the nursing home, the assessing step including taking a first plurality of subepidermal moisture (SEM) measurements of the patient; calculating a first delta value from a portion of the first plurality of SEM measurements; determining whether the first delta value exceeds a first threshold; administering a level-0 first intervention if the first delta value does not exceed the first threshold; and administering a level-N first intervention if the first delta value exceeds the first threshold, wherein N is an integer and N has a value greater than or equal to 1. In some embodiments, the incidence of ulcers in nursing home patients is reduced to less than 1 in 100, less than 1 in 200, less than 1 in 300, less than 1 in 400, less than 1 in 500, less than 1 in 600, less than 1 in 700, less than 1 in 800, less than 1 in 900, or less than 1 in 1000.

[0101] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a protective cream to the patient's heel, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements on the patient's heel; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the protective cream to the patient's heel if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every two hours if the delta value exceeds the threshold value. In one aspect, the plurality of SEM measurements are taken at least once every hour or at least once every 30 minutes if the delta value exceeds the threshold value.

[0102] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of neuromuscular stimulation of the patient's heel, the method comprising the steps of: taking multiple subepidermal moisture (SEM) measurements at the patient's heel; calculating a delta value from a portion of the multiple SEM measurements; determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2; administering neuromuscular stimulation to the patient's heel if the delta value exceeds the threshold; and taking multiple SEM measurements every hour if the delta value exceeds the threshold. In an aspect, the multiple SEM measurements are taken at least once every 30 minutes if the delta value exceeds the threshold.

[0103] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a topical cream to the patient's heel, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements on the patient's heel; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the topical cream to the patient's heel if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every 30 minutes if the delta value exceeds the threshold value.

[0104] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a protective cream to the patient's sacrum, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2; applying the protective cream to the patient's sacrum if the delta value exceeds the threshold; and taking a plurality of SEM measurements every six hours if the delta value exceeds the threshold. In certain aspects, the plurality of SEM measurements are taken at least once every four hours, at least once every three hours, at least once every two hours, at least once every hour, or at least once every 30 minutes if the delta value exceeds the threshold.

[0105] In certain aspects, the present disclosure provides and includes a method of identifying and treating a patient in need of neuromuscular stimulation at the patient's sacrum, the method comprising the steps of: taking multiple subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the multiple SEM measurements; determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2; administering neuromuscular stimulation to the patient's sacrum if the delta value exceeds the threshold; and taking multiple SEM measurements every four hours if the delta value exceeds the threshold. In certain aspects, the multiple SEM measurements are taken at least once every three hours, at least once every two hours, at least once every hour, or at least once every 30 minutes if the delta value exceeds the threshold.

[0106] In one aspect, the present disclosure provides and includes a method for identifying and treating a patient in need of application of a topical cream to the patient's sacrum, the method comprising the steps of: taking a plurality of subepidermal moisture (SEM) measurements at the patient's sacrum; calculating a delta value from a portion of the plurality of SEM measurements; determining whether the delta value exceeds a threshold value corresponding to level N, where N is greater than or equal to 2; applying the topical cream to the patient's sacrum if the delta value exceeds the threshold value; and taking a plurality of SEM measurements every two hours if the delta value exceeds the threshold value. In an aspect, the plurality of SEM measurements is taken at least hourly or at least once every 30 minutes if the delta value exceeds the threshold value.

[0107] In some embodiments, the disclosed methods are carried out using the apparatus disclosed in U.S. Patent Application Nos. 14 / 827,375 and 15 / 134,110. In one embodiment, the moisture content is equivalent to the SEM value on a predetermined scale. In some embodiments, the predetermined scale can range from 0 to 20, e.g., 0 to 1, 0 to 2, 0 to 3, 0 to 4, 0 to 5, 0 to 6, 0 to 7, 0 to 8, 0 to 9, 0 to 10, 0 to 11, 0 to 12, 0 to 13, 0 to 14, 0 to 15, 0 to 16, 0 to 17, 0 to 18, 0 to 19, etc. In one embodiment, the predetermined scale can be increased or decreased by a factor or multiple based on the values ​​provided herein.

[0108] In some embodiments, the present disclosure further provides and includes providing targeted treatment to a patient's anatomical location identified as damaged by a combination of visual assessment and SEM scan measurements. In one embodiment, targeted treatment is provided to a common site for pressure ulcers selected from the group consisting of the toes, heels, sacrum, spine, elbows, scapula, occipital region, and ischial tuberosity. In some embodiments, targeted treatment is simultaneously provided to a second common site for pressure ulcers selected from the group consisting of the toes, heels, sacrum, spine, elbows, scapula, occipital region, and ischial tuberosity. In one embodiment, the first site receiving targeted treatment is known to cause the development of pressure ulcers in the second site.

[0109] The present disclosure is illustrated by the following examples. The examples set forth herein illustrate some aspects of the present disclosure, but should not be construed as limiting the scope of the disclosure in any way. [Example]

[0110] Example 1: Intervention Levels for Treating Pressure Ulcers on the Heel

[0111] Subjects identified as being at risk for pressure ulcers on the heel were treated according to the following scheme:

[0112] [Table 1]

[0113] Example 2: Intervention Levels for Treating Pressure Ulcers in the Sacrum

[0114] Subjects identified as being at risk for sacral pressure ulcers were treated according to the following scheme:

[0115] [Table 2]

[0116] Example 3: Identification of Patients Requiring Sacral Level-0 Intervention

[0117] The patient underwent multiple SEM measurements at and around the bony prominence of the sacrum using a device capable of taking SEM measurements. Before performing the measurements, surface moisture and material on the patient's skin surface was removed. The electrodes of the device were applied to the patient's skin with sufficient pressure to ensure complete contact for approximately one second to obtain each SEM measurement.

[0118] SEM measurements were taken along a line across the patient's sacrum. Multiple measurements were taken at a given measurement location. Figure 2A shows a sample visual assessment of healthy tissue. Figure 2B shows the corresponding plot of the mean values ​​of the SEM measurements taken at each location. A threshold of 0.5 was selected. The delta value was calculated as the difference between the maximum and minimum mean SEM values, which was determined to be less than 0.5. Because the SEM delta value fell below the threshold, the patient was identified as requiring level-0 intervention. Therefore, the patient was placed on a standard mattress and repositioned every 24 hours.

[0119] Further SEM measurements were taken every 24 hours until discharge. There was no change in intervention levels.

[0120] Example 4: Identification of patients requiring level-n intervention in the sacrum

[0121] Patients underwent multiple SEM measurements taken in a line across the sacrum, following a procedure similar to that described in Example 3.

[0122] Figure 3A shows a sample visual assessment of the injured tissue. Figure 3B shows the corresponding plot of the mean SEM measurements taken at each location. A threshold of 0.5 was selected. The delta value was calculated as the difference between the maximum and minimum mean SEM values, which was determined to be greater than 0.5. Because the SEM delta value exceeded the threshold by more than 200%, the patient was identified as requiring Level-8 intervention. Therefore, the patient was placed on a silicone pad and monitored hourly until an SEM delta value less than 170% of the threshold was observed, at which point the patient was switched to Level-7 intervention.

[0123] Example 5: Example of a selection process for levels of intervention and monitoring

[0124] 4 is a diagram of a process 400 for selecting a level of intervention and monitoring based on the amount by which delta values ​​from SEM measurements exceed a threshold. Here, in step 402, a caregiver uses an SEM scanner to take multiple SEM measurements at a location on a patient's skin, with each measurement producing one SEM value. In step 404, a portion of these SEM values ​​are used to calculate a delta value "Δ." The delta value is calculated by subtracting the smallest SEM value from the largest SEM value produced from the multiple SEM measurements.

[0125] The calculated delta value was compared to a threshold "T" in step 406. If the delta value was less than or equal to the threshold, step 408 was performed in which the caregiver waited until the monitoring interval associated with the current level of care occurred and then repeated the SEM measurement in step 402. If the delta value was greater than the threshold, the amount by which the delta value exceeded the threshold was compared to a cascading series of different values.

[0126] In some instances, the delta value was positive and the comparison was performed by subtracting the threshold value from the delta value, which resulted in a positive difference, and then a determination was made as to whether that difference exceeded a first difference D1 in step 410. If the difference was less than D1, processing proceeded to step 412 and then step 414, where an intervention and measurement interval, each associated with level −N+1, was implemented. In this example, N was a value greater than or equal to zero.

[0127] In some cases, the delta value is negative, for example, if the SEM measurement at the center of the data in Figure 3B is subtracted from the average of the SEM values ​​from the leftmost to the rightmost locations in Figure 3B. In that case, the differences Dl, D2 through Dn were selected to have negative values ​​that would have different absolute values ​​than the corresponding difference values ​​Dl, D2 through Dn used for positive delta values. Alternatively, the comparisons in steps 410, 420, and 430 were changed to "≦" instead of "≧" as shown in Figure 4.

[0128] Example 6: Workflow Guidance Matrix

[0129] FIG. 5 is an example of a workflow guidance matrix 500 that uses a current intervention level 502 and a new delta value 504 to select a new intervention level 506. Here, a caregiver monitored a patient's condition by periodically taking multiple SEM measurements at one or more locations on the patient's skin. At the time of these measurements, the patient received care associated with a certain level of intervention and monitoring. In this example, Level-0 (zero) is associated with patients who were not considered to be at significant risk for developing a pressure ulcer. Higher levels of intervention and monitoring were identified by tiers of intervention ranked according to, for example, cost, difficulty of implementation, or other parameters identified by the care facility. When a caregiver was taking a new set of SEM measurements, they consulted this matrix by identifying the row of the current intervention level 502, the delta value determined from the most recent set of SEM measurements 504, and the intervention level in the cell 506 where the row 502 and column 504 intersected. The caregiver could consider not only the identified intervention level, but also the current intervention level and the delta value when selecting a level of intervention for the next time interval.

[0130] In some instances, the new intervention level values ​​in cells 506 were similar across rows. In some instances, the new intervention level values ​​in adjacent cells 506 differed by one level or more than one level. In some instances, the new intervention level values ​​in adjacent cells 506 were identical in adjacent cells.

[0131] Example 7: Progression of tissue conditions leading to pressure ulcers

[0132] 6A, 6B, and 6C illustrate illustrative, non-limiting examples of the progression of tissue conditions over time that lead to pressure ulcers. FIG. 6A illustrates a cross-section of healthy tissue 600, including the stratum corneum 602 and healthy cells 604 in the epidermis / dermis. The center electrode 606 and toroidal electrode 608 of the SEM scanner are shown in cross-section in contact with the stratum corneum 602. An illustrative representation of the sensitive region of the SEM scanner is shown as elliptical region 610. This region 610 has a certain depth of sensitivity. In some instances, the depth of sensitivity is in the range of 0.14 to 0.16 inches. In some instances, the depth of sensitivity is less than 0.16 inches.

[0133] 6B shows an illustrative cross-section of slightly damaged tissue 620. Cellular damage, such as that resulting from prolonged application of low levels of pressure, has affected the tissue. Without being limited by theory, some of the cells 622 rupture, releasing their fluid contents into the intercellular spaces 624. Alternatively, and without being limited by theory, an inflammatory response causes fluid to move into the intercellular spaces 624. This damage is not visible on the skin surface.

[0134] 6C is an illustrative cross-section 640 of a more advanced level of damage. Without being limited by theory, it is possible that the tissue now has largely ruptured cells 622, resulting in small mechanical structures that transmit continued pressure. As the tissue thickness decreases, bone 642 now comes closer to the skin surface. The ruptured cells 622 and the intercellular spaces 624 are compressed, forcing fluid 644 out of the local tissue, as indicated by arrows 646.

[0135] FIG. 6D is an illustrative plot 660 of delta values ​​for one patient at a single location with a pressure ulcer. SEM values ​​were measured by an SEM scanner. Delta values ​​were generated from a set of SEM measurements taken at incremental times. Point 672 is the measurement at time=0, when all of the SEM values ​​have the baseline value associated with healthy tissue and the delta value is zero. At time t1, another set of SEM measurements was taken, and the associated delta value is shown as point 674. This delta value was below threshold 662 and therefore did not indicate significant subsurface damage.

[0136] At time t2, the damage had progressed and the delta value 676 was greater than the threshold value 662, indicating significant damage. This damage was not yet visible on the skin. Nevertheless, the delta value being greater than the threshold value 662 indicated cellular damage at a depth shallower than the depth of sensitivity of the SEM scanner.

[0137] At time t3, the injury continued, but the amount of fluid in the intercellular spaces decreased due to mechanical extrusion as shown in Figure 6C, which reduced the SEM value obtained over the injured area, which in turn reduced the calculated delta value 678 since the SEM value of the healthy tissue remained almost the same as during the previous measurements.

[0138] At time t4, the damage has progressed to the point where it is visible at the skin surface, as shown in FIG. 3A. In some instances, time t4 may occur before one or both of t2 and t3. In some instances, time t4 may occur after the delta value reaches zero again along curve 670 after time t3 but before t5. Arrow 665 indicates that the damage remained visible after time t4. In some instances, the tissue may be considered a "Stage 1" pressure ulcer after time t4.

[0139] At time t5, the injury had progressed to the point where enough fluid had been extruded from the local tissue that the SEM value of a measurement made across the injured area was less than the SEM value of healthy tissue. As shown in FIG. 3B, this resulted in a negative delta value 680. In some instances, a negative delta may indicate severe tissue damage. In some instances, a negative delta may indicate that a portion of the tissue has died at the location of the lowest SEM value.

[0140] Example 8: Method I for mapping areas of possible damage

[0141] FIG. 7A shows an example of how to map areas of possible damage. Damaged area 700 was surrounded by healthy tissue 708. Central area 730 was significantly damaged. A first peripheral area 720 was less damaged, and a second peripheral area 710 was less damaged but still not healthy tissue. The skin covering all of these areas had a similar appearance and texture and did not indicate subsurface damage. A series of dashed circles 740, 742, 744, 746, 748, and 750 show an example set of locations where SEM measurements were taken. SEM measurements taken at locations 740, 742, and 750 generally produced SEM values ​​associated with healthy tissue, identified in this example as "H." SEM measurements taken at locations 744 and 748 generally produced SEM values ​​"J," slightly greater than H. SEM measurements taken at location 746 generally produced SEM values ​​"P," greater than J. All of these measurements were considered to have been made at a single "location" on the patient's body, e.g., the sacrum, even though the individual locations were spatially dispersed throughout this location. For this set of SEM values, the delta was taken as the difference between the highest SEM value within this set, which likely occurred at location 746, and the lowest SEM value, which likely occurred at one of locations 740, 742, and 750. If the delta was greater than a threshold "T," this indicated significant damage at this location. The exact location of the greatest damage was likely close to measurement location 746, which produced the largest SEM value.

[0142] Example 9: Method II for mapping areas of possible damage

[0143] FIG. 7B shows a second example of mapping the area of ​​potential damage. In this example, the approximate location of the greatest damage was known, for example, by prior application of the method shown in FIG. 7A. The intent of this method was to map the boundary between area 710 and area 720 to determine the extent of the damage. For simplicity, the SEM values ​​produced by measurements within each area were the same, and the SEM values ​​increased from area 710 to area 720 to area 730. The first SEM measurement was made at location 760, which was known to be the approximate location of the greatest damage. Subsequent measurements were made at locations 762, 764, 766, and 768, in the order shown by path 780. The SEM value produced at location 764 was slightly larger than the SEM values ​​produced at locations 762 and 766, indicating that location 764 was partially within area 720, while locations 762 and 766 were entirely within the less damaged area 710. The boundary could be approximated by interpolating between the various measurement locations. For example, the SEM value generated at location 770 was large enough to suggest that it was entirely within area 720 and therefore did not help identify the boundary between areas 710 and 720. Therefore, the subsequent location 772 was quite far from the starting location 760. In this example, location 760 is now entirely within area 710, so the boundary between areas 710 and 720 could be interpolated as being between locations 770 and 772. The SEM value generated by the measurement at location 774 was similar to the SEM value from location 770, so it could be sufficient to identify the boundary as outside of location 774 without taking another measurement at a location corresponding to location 772.

[0144] This set of measurements allowed the creation of a map of a particular level of damage, e.g., area 720. Repeating this mapping process at regular time intervals would provide an indication as to whether area 720 is expanding, which may indicate that an increased level of intervention is appropriate, or whether area 720 is shrinking, which may indicate that the current level of intervention is allowing the damage to heal.

[0145] Example 10: Treatment decision pathways for patient stratification and delivery of appropriate treatment

[0146] Figure 8A outlines the currently recommended treatment decision pathway for preventing pressure ulcers in hospitalized patients, as presented by the National Institute for Health and Care Excellence (NICE) in their clinical guideline, "Pressure ulcers: prevention and management," published April 23, 2014. The guideline recommended that a risk analysis be performed for all patients admitted to a care facility who present with one or more risk factors, such as significantly limited mobility, significant loss of sensation, previous or current pressure ulcers, nutritional impairment, inability to position themselves, or significant cognitive impairment. Risk assessment is typically performed using a scoring checklist, such as the Braden Scale, which assesses the severity of specific risk factors.

[0147] Once the risk assessment is complete, patients are identified as being at (i) low risk for developing a pressure ulcer, (ii) at risk for developing a pressure ulcer, or (iii) at high risk for developing a pressure ulcer. Patients are classified as having a level of risk and are evaluated by various procedural procedures and visual assessments.

[0148] All patients are potentially at risk for developing pressure ulcers. They are more likely to occur in people who are seriously ill or who have neurological diseases, movement disorders, nutritional disorders, poor posture, or deformities.

[0149] Pressure ulcers are classified as Stage 1 to Stage 4, with Stage 1 being the least severe. The National Pressure Ulcer Advisory Panel (NPUAP) defines a "Stage 1" ulcer as intact skin with a localized area of ​​non-blanchable erythema, where "blanchable" indicates loss of all redness of the tissue when pressure is applied; "non-blanchable" tissue remains red when pressure is applied due to the presence of red blood cells outside of the blood vessels (extravasation). In some patients, the blanchable erythema or changes in sensation, temperature, or consistency may precede visible changes.

[0150] Visual skin assessment (VSA) is the current method for identifying pressure ulcers. Trained healthcare professionals visually and tactilely assess the appearance of the skin, looking for redness or variations in tissue firmness, tissue temperature, or moisture.

[0151] If a patient is identified as being at low risk for developing a pressure ulcer, the patient is simply monitored for changes in clinical status, such as undergoing surgery, worsening of underlying disease, or changes in mobility. Patients who use a wheelchair or are sedentary for extended periods of time may be given a high performance foam cushion or equivalent pressure-redistributing cushion. If there is no change in clinical status, low-risk patients will not be reassessed under this set of guidance and will remain on the same treatment and evaluation pathway until they leave the care facility.

[0152] If a patient is identified as at risk of developing a pressure ulcer, they will be scheduled to be repositioned, or "turned," every six hours. If the patient is wheelchair bound or seated for extended periods, as in the case of low-risk patients, they may be given a high-performance foam cushion. No other monitoring or intervention is recommended by the NICE guidelines.

[0153] High-risk patients will be given a high-performance foam mattress as a preventative measure, a high-performance cushion if they use a wheelchair or are seated for extended periods, and will be repositioned every four hours. Patients will undergo daily VSA on all body areas. If areas with persistent erythema are found, appropriate intervention will be implemented, and the area will be rechecked with VSA every two hours. Areas not showing persistent erythema will be rechecked with VSA daily. An individualized care plan will be developed for each high-risk patient.

[0154] From this flowchart, we can see that the majority of caregiver time will be spent with high-risk patients. While this may be appropriate, at-risk patients remain unmonitored and may develop a Stage 1 ulcer before symptoms are observed by the caregiver. Furthermore, a consequence of relying on VSA to detect problems inevitably means that patients will develop a Stage 1 ulcer before intervention can be selected or implemented. By the time damage progresses to Stage 1, it is likely that the skin will have broken down, resulting in a Stage 2 ulcer, despite intervention. There is a clear need to identify tissue damage earlier so that intervention can prevent subepidermal damage from progressing to Stage 1 and beyond.

[0155] Figure 8B is an example of a current expanded treatment decision pathway for pressure ulcer prevention currently implemented in some healthcare facilities. The expanded pathway adds a monitoring step to both the at-risk and low-risk pathways. Low-risk patients undergo weekly risk assessments, such as a Braden scale assessment. Patients identified as at-risk at the initial assessment are provided with a high-performance foam mattress as a preventative measure and are also assessed daily with a VSA. A care plan is developed to monitor and treat the at-risk patient. For high-risk patients, there is no change in care.

[0156] The expanded plan has the advantage of providing baseline monitoring of all patients for pressure ulcers. However, the additional steps require additional time by adding staff and placing additional strain on existing staff. While the care pathway in Figure 8B is superior to the recommended care pathway in Figure 8A, it requires more resources and still suffers from the limitation that patients must develop a Stage 1 ulcer before the injury can be identified with VSA.

[0157] Various hospitals and nursing homes use a variety of risk categories, ranging from two categories, low risk and high risk, to four or more categories, such as "very high risk," in addition to the categories in the example of Figure 8B. Patients are assigned to various categories based on the results of their initial risk assessment.

[0158] FIG. 9 is an example flowchart of how an SEM scanner may be used in a stand-alone pressure ulcer prevention treatment in accordance with the present disclosure. All incoming patients undergo a complete SEM scanner evaluation of all body locations selected for monitoring. These selected locations may include areas recommended in the SEM scanner's Instructions for Use (IFU), such as the sacrum and both heels. Additional locations may be identified by the hospital and integrated into hospital practice. Multiple SEM measurements are taken at spaced locations at and around each body location, generally referred to as taking multiple measurements at a body location. The SEM scanner calculates a "delta" value for each location from the set of measurements taken at and around that location. The delta value is then compared to one or more thresholds to classify the patient. In this example, patients are assigned to one of two risk categories: low risk and at risk.

[0159] In some embodiments, the clinician will perform SEM scans of body locations identified in the initial SEM scan as having possible damage at a first time interval. The clinician will also perform SEM scans of all other body locations selected for monitoring at a second time interval that is longer than the first time interval. In some embodiments, the values ​​of the first and second time intervals depend on the risk classification to which the patient is assigned. For example, a high-risk patient will have a first time interval of 4 hours and a second time interval of 1 day, while an at-risk patient will have a first time interval of 1 day and a second time interval of 1 week. In some embodiments, the time intervals may not be strictly time-based but may be event-based, such as upon a change in personnel or a shift change. Generally, body locations with elevated delta values ​​will be scanned more frequently than other body locations being monitored that had normal delta values ​​in previous SEM scans.

[0160] In some embodiments, the interval at which SEM scans are performed is determined by the delta value from the previous SEM scan. For example, if a previous SEM scan of a body location had a delta value equal to or greater than a first threshold, SEM scans are performed at a first time interval, while if a previous SEM scan of a body location had a delta value equal to or greater than a second threshold that is greater than the first threshold, SEM scans are performed at a second time interval that is shorter than the first time interval.

[0161] In this example, low-risk patients undergo weekly SEM scans of all body locations selected for monitoring. This is a small effort that provides basic protection for even the healthiest patients, as weekly SEM scans are likely to detect tissue damage before it becomes visible on VSA.

[0162] At-risk patients, which would include patients who would be identified as high risk in the current care pathway of Figures 8A and 8B, would receive specialized care based on the body location exhibiting a delta value above the threshold. For example, if the sacral body location has a delta value above the threshold, the patient would be turned every six hours and receive a daily SEM scan of the sacrum and weekly SEM scans of other body locations.

[0163] 10 is an example flowchart of how an SEM scanner can be used as an aid to further refine the expanded treatment decision pathway of FIG. 8B in accordance with the present disclosure. Incoming patients undergo both a risk assessment and an SEM scan of all body locations identified by the hospital for monitoring, and the patient's assignment to a risk category is based in part on the risk assessment and in part on the SEM scan results. An initial delta value greater than a threshold indicates potential damage at that body location. In some embodiments, the assignment is based solely on the largest initial delta value found during the initial SEM scan.

[0164] The decision to perform an intervention, such as repositioning the patient at a first interval, is currently based on VSA and risk assessment, despite uncertainty about whether there is early-stage damage under the skin. In one aspect, the decision to perform an intervention at a particular body location or a conventional intervention, such as a high-performance mattress, is based on the delta value revealed at that location in the SEM scan. If the delta value is less than a predetermined threshold, no intervention is necessary. If the delta value is greater than a predetermined threshold, then an intervention is selected and performed based in part on the body location and in part on the delta value at that body location. The predetermined threshold for whether to select and perform an intervention may be greater or less than the threshold for determining whether there is potential damage at a body location.

[0165] One advantage of utilizing an SEM scanner to monitor patients is highlighted by comparing the costs of providing the care pathways in Figures 8A, 8B, 9, and 10. Note that the costs quoted herein are for patients who do not have or have not developed pressure ulcers, in which case the expected cost of treatment rises to $2000 for a stage 1 ulcer.

[0166] The baseline for this comparison is the expanded current practice in Figure 8B, which represents current "best practice" for hospitals striving to reduce the incidence of pressure ulcers. Providing care for the low-risk care pathway is expected to cost an average of $26 per patient for an average length of stay of 5.6 days, care for at-risk patients is expected to cost an average of $121, and high-risk patients are expected to cost $165. All care pathways rely on VSA to detect pressure ulcers and otherwise implement interventions based on the progression of a "typical" patient rather than specific patient symptoms.

[0167] As shown in Figure 10, integrating an SEM scanner into the current "best practice" workflow does not reduce the cost of any of the care pathways because no work elements are eliminated. The benefit is the ability to detect tissue damage at an early stage with minimal incremental cost. The incremental cost of adding an SEM scan to a no-risk care pathway is $2, raising the cost from approximately $26 to $28. The expected cost of caring for at-risk patients who do not have a high SEM scan delta, i.e., no subepidermal tissue damage, also increases by $2. However, if an at-risk patient is found to have a high SEM scan delta, the patient will be elevated to the high-risk category, where the expected cost of care will increase from $165 to $169. While this may seem like an additional expense at first glance, it represents an increased level of protection provided to at-risk patients.

[0168] Figure 9 depicts an example workflow that relies solely on the SEM scanner to monitor patients and does not perform conventional VSA. The expected cost of preventative care for low-risk patients is $4, compared to a cost of $28 for the integrated low-risk care pathway of Figure 10. For at-risk patients, who are simply another classification for the SEM scanner care pathway of Figure 9, the expected cost is $97, compared to $123 to $169 for at-risk and high-risk patients for the integrated care pathway of Figure 10.

[0169] 11 illustrates the concept of providing continuity of care across multiple care settings in accordance with the present disclosure. This example shows a care pathway 1100 for a patient who is to be cared for continuously in multiple care settings, beginning in a home care setting 1110. A decision is made to transfer the patient to a hospital 1150 where the patient is initially admitted to a medical / surgical (med / surg) unit 1120. After receiving care in the med / surg unit 1120 for a period of time, the patient is transferred to a long-term care unit 1130 within the same hospital 1150. After further treatment, the patient is discharged from the hospital 1150 to a skilled nursing facility 1140. Although not shown in Figure 11, the care pathway 1100 is not limited to this sample combination of procedures and care settings. For example, the care pathway 1100 may also involve discharging a patient back to a home care setting.

[0170] In one embodiment, a central "registry" or database 1160 is provided that collects data from all care settings as well as patient status as they move between care settings.

[0171] While in each care environment, for example, a home care environment 1120, health information about the patient is recorded in data records 1112 and transferred to database 1160. Health information may include tests or tests, observations, measurements, treatment results, implementation of interventions intended to prevent the development of pressure ulcers, dietary records, and other records related to the patient's symptoms and treatment. Data records from the care environment may include the patient's identifier, one or more of the following data elements from the following groups: nutritional information, interventions performed, risk assessment, visual skin assessment, care plan, physician's notes, lean events, vital signs, "health measures" such as skin redness or mobility indicators or cognitive measures, weight, and laboratory results, and a date / time associated with the data element. Data records may vary in structure and content. Data records reported to the database may contain one of several of the following data elements: a) Patient Identifier b) The date of the transaction c) Facility identifier d) Location of the transaction e) Nutritional information f) interventions implemented g) Risk assessment h) Visual skin evaluation i) Care plan j) Physician's notes (diagnosis, instructions, prescriptions, test requests, procedures, treatments, etc.) k) The results of any test, procedure or action l) Event m) Vital signs n) Weight o) Laboratory Results

[0172] When a patient is transferred between care settings, for example, from a home care setting 1110 to a med / surg care setting 1120, a transfer record 1114 is created and reported to database 1160. Transferring information regarding risk and health information associated with pressure ulcers will improve the care provided at the new care setting. In some embodiments, the transfer record 1114 includes an assessment of the patient performed at the “from” care site after the decision to transfer the patient was made. In some embodiments, the assessment includes a SEM scan of at least one body location, where the SEM scan includes multiple SEM values ​​measured at a single body location and a calculation of a delta value from the multiple SEM values. In some embodiments, the transfer record contains a history of previous SEM and / or delta values ​​while at the “from” care environment. In some embodiments, the transfer record includes one or more of a VSA, a risk analysis, and other health data. The transfer record may contain one of more than one of the following data elements: a) Patient Identifier b) Date / time of the transaction (date and time, time zone or Greenwich Mean Time) c) Transaction type (pre-admission, admission, transfer, discharge, etc.) d) "Relocation" location e) "From" location f) Facility / unit identification name g) Risk assessment h) Visual skin evaluation i) Photographs of body locations

[0173] A patient may be periodically transferred from a primary care environment, such as a home care environment 1110, to a higher level care environment, such as a long-term acute care unit 1130, where the patient receives "episodes of care" from physicians or other specialists. Data records of assessments and care provided in the higher level care environment are reported to database 1160. Upon discharge from the long-term acute care environment 1130 to the home environment 1110, the data records contain care instructions, prescriptions, and other guidance for care in the home environment 1110.

[0174] With data from the entire care pathway 1100 collected in database 1160, it is possible to query database 1160 to retrieve delta values ​​observed over time for a particular patient across multiple care settings and various episodes of care.

[0175] In some embodiments, the query is configured to determine whether an indication from patient monitoring and / or treatment is continuing.

[0176] In some embodiments, the query is configured to determine whether the patient's treatment is effective.

[0177] In some embodiments, the query is configured to determine whether the patient outcome is related to one or more of the data elements reported in database 1160 .

[0178] In some embodiments, the query is configured to retrieve one or more health measures in addition to the delta values ​​to assess possible links between the retrieved health measures and the development of pressure ulcers or other outcomes (evolution of other health conditions). The delta values ​​are plotted against the date / time of measurement to form a time history of delta values ​​for a body location. In some embodiments, the delta values ​​are analyzed to determine one or more of slope, acceleration, curve shape and related characteristics, and time-to-intercept for a selected threshold. In some embodiments, the results of these analyses can be used to implement the methods and processes of FIGS. 1 and 4.

[0179] From the foregoing, it will be appreciated that the present disclosure can be embodied in a variety of ways, including but not limited to:

[0180] While the present disclosure has been described with reference to particular embodiments, those skilled in the art will recognize that various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the disclosure. Furthermore, many modifications may be made to adapt a particular situation or material to the teachings of the disclosure without departing from the scope of the disclosure. Therefore, the disclosure is not intended to be limited to the particular embodiments disclosed, but rather, it is intended that the disclosure will include all embodiments falling within the scope and spirit of the appended claims.

Claims

1. 1. A method of providing continuity of care to a patient during transfer between care settings, comprising: determining to transfer the patient from the first care setting to a second care setting; performing a first assessment of the patient in a first care setting; creating a transfer record for the assessment; and transferring the transfer record along with the patient to a second care setting.

2. The method of claim 1 , wherein the first assessment comprises performing a subepidermal moisture (SEM) scan of at least one body location of the patient.

3. The method of claim 2 , wherein the SEM scan comprises taking a plurality of measurements of SEM values ​​at the body location and calculating a delta value from the plurality of SEM values.

4. performing a plurality of SEM scans of the patient at different times while in the first care environment; and recording a delta value from each of the SEM scans, wherein the decision to transfer the patient is based in part on the delta values ​​recorded while at the first care setting.

5. The method of claim 4 , wherein the transfer record includes the delta values ​​from some of the plurality of SEM scans of the patient taken at different times while in the first care environment.

6. The method of claim 2 , wherein SEM scans are performed at all body locations identified for monitoring.

7. The method of claim 1 , wherein the first assessment includes at least one of a risk assessment of the patient, a visual skin assessment of the at least one body location of the patient, and an image of the at least one body location.

8. The method of claim 1 , wherein the transfer record includes at least one of a transaction type, a transaction date / time, a "transfer to" location, and a "transfer from" location.

9. performing a first SEM scan of at least one body location of the patient while in the first care environment, the first SEM scan including a plurality of measurements of SEM values ​​at the body location and calculating a first delta value from the plurality of SEM values; creating a first data record including the first delta value; reporting the first data record to a database; and b. reporting said translocation record to said database.

10. the first data record includes a patient identifier and a first date / time when the first SEM scan was performed; 10. The method of claim 9, wherein the transfer record also includes an identifier for the patient and a second date / time when the first evaluation was performed.

11. performing an SEM scan of at least one body location of the patient while in the second care environment to calculate a second delta value; creating a second data record including the patient identifier, the second delta value, and a third date / time when the second SEM scan was performed; and reporting the second record to a database.

12. The method of claim 11 , further comprising querying the database to retrieve a portion of a data record that includes a delta value for the at least one body location of the patient.

13. formatting the retrieved delta values ​​in date / time order; and displaying the formatted delta value.

14. creating a further data record including the patient's identifier, data elements from the following groups: nutritional information, interventions performed, risk assessment, visual skin assessment, care plan, physician's notes, lean events, vital signs, weight, and laboratory results, and dates / times associated with the data elements; The method of claim 10, further comprising the step of reporting the additional data records to the database.

15. 14. The method of claim 13, wherein the formalized delta values ​​are displayed in the form of a curve.

16. 16. The method of claim 15, further comprising analyzing the retrieved delta values ​​to determine one or more of slope, acceleration, curve shape and associated characteristics, and intercept versus time for a selected threshold.

17. 17. The method of claim 16, wherein the acceleration is determined by the rate of change of the slope of the curve.

18. 17. The method of claim 16, wherein the decision to relocate the patient is based in part on one or more of the slope, the acceleration, the curve shape and associated characteristics, and a selected threshold intercept with respect to time.

19. performing an SEM scan of the at least one body location of the patient while in a third care environment to calculate a third delta value; 12. The method of claim 11, further comprising the steps of: creating a third data record including the patient's identifier, the three delta values, and a fourth date / time when the third SEM scan was performed; and reporting the third data record to a database.

20. 20. The method of claim 19, further comprising querying the database to retrieve observed delta values ​​over time for a particular patient across multiple care settings and various episodes of care.

Images